Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EPS (Weighted Average and Diluted) (2019 - 2025)

Bicycle Therapeutics (BCYC) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.85 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 14.86% year-over-year to -$0.85, compared with a TTM value of -$3.62 through Sep 2025, down 11.04%, and an annual FY2024 reading of -$2.9, up 42.91% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.85 for Q3 2025 at Bicycle Therapeutics, up from -$1.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.59 in Q3 2021 and bottomed at -$1.41 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.91, with a median of -$0.88 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 65.57% in 2022, then surged 52.31% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then crashed by 65.57% to -$1.01 in 2022, then decreased by 11.88% to -$1.13 in 2023, then skyrocketed by 33.63% to -$0.75 in 2024, then dropped by 13.33% to -$0.85 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BCYC at -$0.85 in Q3 2025, -$1.14 in Q2 2025, and -$0.88 in Q1 2025.